NASDAQ:APOP - CELLECT BIOTECH/S Stock Price, Forecast & News

CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."

CELLECT BIOTECH/S (NASDAQ:APOP) posted its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. View CELLECT BIOTECH/S's Earnings History.

CELLECT BIOTECH/S is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for CELLECT BIOTECH/S.

1 brokerages have issued 1-year price targets for CELLECT BIOTECH/S's stock. Their forecasts range from $12.00 to $12.00. On average, they expect CELLECT BIOTECH/S's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 352.8% from the stock's current price. View Analyst Price Targets for CELLECT BIOTECH/S.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELLECT BIOTECH/S.

Press coverage about APOP stock has trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CELLECT BIOTECH/S earned a news impact score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for CELLECT BIOTECH/S.

Some companies that are related to CELLECT BIOTECH/S include Neovasc (NVCN), Titan Medical (TMDI), DarioHealth (DRIO), Biostage (BSTG), Co-Diagnostics (CODX), Interpace Diagnostics Group (IDXG), RA Medical Systems (RMED), Avinger (AVGR), Obalon Therapeutics (OBLN), Valeritas (VLRX), Atossa Genetics (ATOS), Hancock Jaffe Laboratories (HJLI), Lianluo Smart (LLIT), Dynatronics (DYNT) and Encision (ECIA).

Based on aggregate information from My MarketBeat watchlists, some companies that other CELLECT BIOTECH/S investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Protalix Biotherapeutics (PLX), Pluristem Therapeutics (PSTI), Allergan (AGN), BIOLINERX LTD/S (BLRX), REDHILL BIOPHAR/S (RDHL), Sangamo Therapeutics (SGMO) and TransEnterix (TRXC).

CELLECT BIOTECH/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (1.48%).

APOP stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APOP stock can currently be purchased for approximately $2.65.

CELLECT BIOTECH/S has a market capitalization of $5.94 million. CELLECT BIOTECH/S employs 28 workers across the globe.View Additional Information About CELLECT BIOTECH/S.

The official website for CELLECT BIOTECH/S is http://www.cellect.co/.

CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]